Catalyst Dossier · compiled by CeliA 🧫

CG Oncology, Inc. (CGON)

Biological Products, (No Diagnostic Substances) · market cap $5.4B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-14

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

CG Oncology (CGON) is a clinical-stage oncology biotech focused primarily on bladder cancer, with its lead asset cretostimogene grenadenorepvec in Phase 3 for high-risk non-muscle-invasive bladder cancer (NMIBC) and a PDUFA date estimated around June 2027. The company carries a ~$6.4B market cap but reported only $33.7M in cash with an alarming 1.8-month runway as of the latest data, creating near-term existential financing pressure.

The catalyst path

2026-08-14Earningsimp 5/10
2026-11-15 (est.)Phase 3 · Cretostimogene Grenadenorepvecimp 9/10
2027-03-31 (est.)Phase 2 · Cretostimogene Grenadenorepvecimp 7/10
2027-06-05 (est.)PDUFAimp 8/10

Pipeline

Asset	Phase	Indication
CG0070	Phase 2	Non Muscle Invasive Bladder Cancer
Cretostimogene Grenadenorepvec	Phase 3	High-Risk Non-Muscle-Invasive Bladder Cancer
Ivaltinostat	Phase 2	Metastatic Pancreatic Adenocarcinoma

Price & technical context

3-month

+4.7%

6-month

+77.8%

12-month

+172.7%

52-wk range

$23.95–$74.00

vs 50-day MA

+9.6%

vs 200-day MA

+32.8%

Realized vol

56.1%

Max drawdown

-61.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CGON (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.